Risks and benefits of biologic therapy for inflammatory bowel diseases.
作者信息
D'Haens Geert
机构信息
Imelda GI Clinical Research Centre, Imeldalaan 9, 2820 Bonheiden, Belgium.
出版信息
Gut. 2007 May;56(5):725-32. doi: 10.1136/gut.2006.103564.
Abstract
摘要
相似文献
1
Risks and benefits of biologic therapy for inflammatory bowel diseases.
Gut. 2007 May;56(5):725-32. doi: 10.1136/gut.2006.103564.
2
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.
Clin Pharmacol Ther. 2017 Oct;102(4):633-641. doi: 10.1002/cpt.791. Epub 2017 Aug 16.
3
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10. doi: 10.1016/j.cgh.2016.04.039. Epub 2016 May 14.
4
Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
Clin Gastroenterol Hepatol. 2018 Jan;16(1):99-105. doi: 10.1016/j.cgh.2017.08.041. Epub 2017 Sep 1.
5
Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2016 Jan;14(1):166-7. doi: 10.1016/j.cgh.2015.04.022. Epub 2015 Apr 27.
6
Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
G Ital Dermatol Venereol. 2011 Aug;146(4):273-81.
7
The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease.
Best Pract Res Clin Gastroenterol. 2020 Feb-Apr;44-45:101670. doi: 10.1016/j.bpg.2020.101670. Epub 2020 Mar 13.
8
Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2015 Feb;13(2):316-21. doi: 10.1016/j.cgh.2014.07.017. Epub 2014 Jul 17.
9
Biologic therapy-induced pemphigus.
An Bras Dermatol. 2017 Jul-Aug;92(4):591-593. doi: 10.1590/abd1806-4841.20176481.
10
Reply.
Clin Gastroenterol Hepatol. 2016 Jan;14(1):167-8. doi: 10.1016/j.cgh.2015.09.012. Epub 2015 Sep 24.
引用本文的文献
1
Cannabidiol Enhances the Therapeutic Efficacy of Olsalazine and Cyclosporine in a Murine Model of Colitis.
Int J Mol Sci. 2025 Aug 16;26(16):7913. doi: 10.3390/ijms26167913.
2
Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.
Pharmaceuticals (Basel). 2025 Mar 27;18(4):478. doi: 10.3390/ph18040478.
3
Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran.
BMC Health Serv Res. 2025 Mar 5;25(1):341. doi: 10.1186/s12913-025-12474-6.
4
Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease.
J Clin Med. 2024 Oct 25;13(21):6408. doi: 10.3390/jcm13216408.
5
IL23R-Specific CAR Tregs for the Treatment of Crohn's Disease.
J Crohns Colitis. 2025 Mar 5;19(3). doi: 10.1093/ecco-jcc/jjae135.
6
Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.
J Clin Med. 2024 Jul 8;13(13):3977. doi: 10.3390/jcm13133977.
7
DNA methylation fine-tunes pro-and anti-inflammatory signalling pathways in inactive ulcerative colitis tissue biopsies.
Sci Rep. 2024 Mar 21;14(1):6789. doi: 10.1038/s41598-024-57440-0.
8
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial.
Inflamm Bowel Dis. 2025 Jan 6;31(1):77-86. doi: 10.1093/ibd/izae040.
9
Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis.
Cureus. 2023 Sep 13;15(9):e45195. doi: 10.7759/cureus.45195. eCollection 2023 Sep.
10
Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn's disease.
Therap Adv Gastroenterol. 2023 Jul 31;16:17562848231188587. doi: 10.1177/17562848231188587. eCollection 2023.
本文引用的文献
1
Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11.
2
Higher incidence of abnormal Pap smears in women with inflammatory bowel disease.
Am J Gastroenterol. 2008 Mar;103(3):631-6. doi: 10.1111/j.1572-0241.2007.01582.x. Epub 2007 Oct 17.
3
Infliximab for rheumatoid arthritis in a patient with tuberculosis.
N Engl J Med. 2006 Aug 17;355(7):740-1. doi: 10.1056/NEJMc053468.
4
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.
5
Infliximab for the treatment of psoriasis.
Expert Opin Biol Ther. 2006 Aug;6(8):797-805. doi: 10.1517/14712598.6.8.797.
6
Risks and benefits of infliximab for the treatment of Crohn's disease.
Clin Gastroenterol Hepatol. 2006 Aug;4(8):1017-24; quiz 976. doi: 10.1016/j.cgh.2006.05.020. Epub 2006 Jul 14.
7
Anti-tumor necrosis factor-alpha-induced psoriasis.
J Rheumatol. 2006 Jul;33(7):1411-4.
8
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275.
9
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Clin Gastroenterol Hepatol. 2006 May;4(5):621-30. doi: 10.1016/j.cgh.2006.03.002.
10
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Eur J Haematol. 2006 Jun;76(6):531-4. doi: 10.1111/j.1600-0609.2006.00646.x. Epub 2006 Mar 17.
Zotero 插件